Adventrx Pharmaceuticals, Inc.

CoFactor results reported showing antitumor activity, lower systemic toxicity

Published in Lab Business Week, November 7th, 2004

Adventrx Pharmaceuticals, Inc., (ANX) announced the results of recent preclinical studies demonstrating enhanced antitumor activity with lower systemic toxicity in a mouse model for colorectal cancer using CoFactor, as compared to leucovorin, in combination with the chemotherapeutic agent 5-fluorouracil (5-FU).

These results suggest replacing leucovorin, the currently used adjunctive agent, with CoFactor in humans could reduce the side effects associated with using 5-FU while simultaneously improving 5-FU's antitumor activity. Results were presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics conference in Geneva, Switzerland on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2004-11-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry